Late treatment study
et al., J. Medical Internet Research, doi:10.2196/21758 (Peer Reviewed)
Efficacy of hydroxych loroquine and tocilizumab in patients with COVID-19: A single-center retrospective chart review
Retrospective 176 hospitalized patients (144 HC
Q, 32 control) showing no significant differences with HC
Q or TCZ. Confounding by indication.
death, ↑37.7%, p=0.54
(odds ratio converted to relative risk)
Please send us corrections, updates, or comments.